Alzamend Neuro Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Alzamend Neuro Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Atlanta
- Headquarters state / province
- Georgia
- Headquarters country
- United States
- Fiscal year end
- April
- Ticker symbol
- ALZN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001677077
- EIN
- 81-1822909
Board of directors
-
Henry Carl Nisser · Director · EVP and General CounselSince 2026
-
Jeffrey Oram · DirectorSince 2026
-
Lynne Fahey McGrath · DirectorSince 2023
-
Mark Gustafson · DirectorSince 2026
-
Milton C. Ault III · DirectorSince 2024
-
Stephan Jackman · Director · Chief Executive OfficerSince 2023
-
William B. Horne · DirectorSince 2023
Chief executives
Stephan Jackman
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of April 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.3%
-
84.4%
-
84.4%
-
84.7%
-
85.2%
-
85.4%
-
85.4%
Board connections
3 of this board's directors also sit on 3 other boards.
- via Henry Carl Nisser, Milton C. Ault III and William B. Horne
- via Henry Carl Nisser and Milton C. Ault III
- via Henry Carl Nisser and Milton C. Ault III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $108,388
- 1 purchase by 1 insider
- Sold, last 12 months
- $949,328
- 11 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 26, 2026 | Milton C. Ault III Director | Open-market sale | −2,000 | $1.56 | $3,116 |
| Apr 14, 2026 | Milton C. Ault III Director | Open-market purchase | +108,388 | $1.00 | $108,388 |
| Dec 23, 2025 | Milton C. Ault III Director | Open-market sale | −1,851 | $2.07 | $3,832 |
| Dec 19, 2025 | William B. Horne Director | Open-market sale | −3,333 | $2.12 | $7,066 |
| Oct 23, 2025 | Lynne Fahey McGrath Director | Open-market sale | −30 | $2.29 | $69 |
| Oct 9, 2025 | Milton C. Ault III Director | Open-market sale | −20,397 | $2.32 | $47,321 |
| Oct 8, 2025 | Milton C. Ault III Director | Derivative conversion | +61,743 | $2.32 | $143,244 |
| Oct 8, 2025 | Milton C. Ault III Director | Open-market sale | −101,394 | $2.44 | $247,401 |
| Oct 7, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
| Oct 7, 2025 | Milton C. Ault III Director | Open-market sale | −57,379 | $2.49 | $142,874 |
| Oct 6, 2025 | Milton C. Ault III Director | Open-market sale | −82,033 | $2.45 | $200,981 |
| Oct 3, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
| Oct 3, 2025 | Milton C. Ault III Director | Open-market sale | −65,903 | $2.44 | $160,803 |
| Oct 2, 2025 | Milton C. Ault III Director | Open-market sale | −20,686 | $2.39 | $49,440 |
| Oct 1, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.